Manohar M

Dr. Manohar M

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2024 in Heliyon
Verified
Journal Article
Open access
CLCynthia Lizzie Lobo
Cynthia Lizzie Lobo
MMManohar M
Manohar M
ASAmitha Shetty
Amitha Shetty
ASAnanya S
Ananya S
PKPallavi K
Pallavi K
Akhilesh DubeyAkhilesh Dubey
Akhilesh Dubey
Breast cancer treatment options are diverse, with tamoxifen commonly used as a selective estrogen receptor modulator (SERM) for hormone receptor-positive breast cancer. However, tamoxifen can have adverse systemic effects. Local transdermal therapy offers a potential solution by delivering the drug directly to the breast and minimizing systemic exposure. Hesperidin, a flavonoid, exerts synergistic effects when combined with anticancer agents. This combination therapy may be a more effective approach to breast cancer management. Analytical methods have been developed to quantify 4-Hydroxytamoxifen (4-HT) and hesperidin separately; however, no method currently exists for their simultaneous quantification in pharmaceutical formulations. This study aimed to develop and validate a reverse-phase high-performance liquid chromatography (RP-HPLC) method for the simultaneous quantification of 4-HT and hesperidin in liposomal formulations. A Design of Experiments (DoE) approach was employed using a Box-Behnken design (BBD) to optimize the RP-HPLC method. BBD allowed for a reduction in the number of required tests by creating a statistical model to estimate the significance of various factors and interactions. The methanol concentration, flow rate, and injection volume were considered as independent variables for optimization. A mobile phase (90:10 ratio of methanol: 0.1% v/v orthophosphoric acid) with a flow rate of 0.4 mL/min, and an injection volume of 10 μL was selected as optimized chromatographic condition. 4-HT showed a retention time (Rt) of 5.05 min and hesperidin showed an Rt of 7.11 min using an optimized analytical method and was detected at 275 nm. The developed RP-HPLC method was validated according to the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines, confirming its accuracy, precision, linearity, selectivity, and robustness. The validated method was then successfully applied to determine the entrapment efficiency and permeation of 4-HT and hesperidin into loaded liposomes. This study fills a gap in the literature by providing a simple and reliable RP-HPLC method for the simultaneous quantification of 4-HT and hesperidin in liposomal formulations.

8 February 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MMManohar M
Manohar M
Akhilesh DubeyAkhilesh Dubey
Akhilesh Dubey
ASAmitha Shetty
Amitha Shetty
Diabetes mellitus (D.M.) is a metabolic disease that has affected over 500 million people globally. Bioactive compounds such as β-carotene and Quercetin have gained research interest for their potential antidiabetic properties, and bioactives have reported superior combinatorial effects in several ailments, including D.M. However, poor oral bioavailability has limited their potential application. Thus, the present study was focused on developing ultrasonically fabricated β-Carotene nanoemulsion (βC-NE) by employing capmul as the oil phase, Gelucire 44/14 as surfactant and Acconon MCM C8 as co-surfactant. The 3 factor- 3 level Box-Behnken design (BBD) was applied to optimise the βC-NE and study the impact of selected independent variables such as % Smix (5 to 9%), amplitude (20–30%) and sonication time (2.5–7.5 min) on responses including globule size (G.S.), poly dispersibility Index (PDI) and entrapment efficiency (E.E.). Further, the combinatorial effect of βC-NE with Quercetin Nanoemulsion (QU-NE) in the streptozotocin-induced diabetic rat model was evaluated. The results exhibited that 7% Smix at 25% amplitude for 5 min produced βC-NE with a droplet size of 153.1 ± 12.25 nm, 0.200 ± 0.04 PDI, and 73.25 ± 3.25% E.E. The βC-NE showed superior in-vivo bioavailability by 5.38 folds. The βC-NE, combined with QU-NE, exhibited potential therapeutic benefits in controlling body weight, blood sugar level, lipid levels, and tissue damage markers. Additionally, the pancreatic cells and hepatic cells were well protected. These results demonstrate the potential benefits of βC-NE and QU-NE in combination and recommend them as a substitute strategy for diabetes.

12 September 2024
Verified
Book Chapter
Closed access
PDF file
Akhilesh DubeyAkhilesh Dubey
Akhilesh Dubey
ASAmitha Shetty
Amitha Shetty
MMManohar M
Manohar M
PJPraneetha Jain
Praneetha Jain

7 January 2025 in International Journal of Applied Pharmaceutics
Verified
Journal Article
Open access
PDF file
MSMahendra Gowdru Srinivasa
Mahendra Gowdru Srinivasa
SGSudeep D Ghate
Sudeep D Ghate
RRR. Shyama Prasad Rao
R. Shyama Prasad Rao
MMManohar M
Manohar M
Objective: This study aimed to identify potential Monoamine oxidase (MAO) inhibitors from Cucurbita pepo to address the increasing prevalence of neurological and neuropsychiatric disorders, such as stroke, Alzheimer's, Parkinson's, autism, migraines, and depression, by targeting key enzymes involved in neurotransmitter degradation. Methods: The study utilised molecular docking and pharmacological, physiological, and ADMET property analyses to screen compounds from Cucurbita pepo. Ten promising MAO inhibitors were shortlisted for further analysis. Extensive Molecular Dynamics (MD) simulations were conducted over 100 nanoseconds to assess the stability and dynamic behaviour within the MAO-A complex. Results: Based on molecular docking results, four shortlisted compounds were identified as potential MAO-A inhibitors. Atomic-level docking studies were used to explore the binding mechanisms of the phytoconstituents within the active site of the MAO-A enzyme. The binding free energies of these compounds ranged from-9.183 to-6.001 kcal/mol. Phytoconstituent Compound C1 had the highest binding affinity with a G score of-9.183 kcal/mol, followed by Compound C2 with a G score of-9.045 kcal/mol. MD simulations further confirmed that both C1 and C2 formed highly stable complexes with MAO-A, suggesting their potential as effective inhibitors. Conclusion: Compounds C1 and C2 from Cucurbita pepo show promise as stable and effective MAO-A inhibitors. Further experimental validation is required to confirm these findings and evaluate their therapeutic potential in treating neurological disorders.

11 June 2026 in Current Drug Targets
Verified
Journal Article
Closed access
PDF file
SMSwastika Maity
Swastika Maity
MSMahendra Gowdru Srinivas
Mahendra Gowdru Srinivas
GNGeetha Nayak
Geetha Nayak
MIMohammed Arfath M I
Mohammed Arfath M I
MMManohar M
Manohar M
ANAkhil Nair
Akhil Nair
Introduction: Multifactorial complex diseases such as cancer, neurodegeneration, and infections are poorly treated with traditional single-target therapies because biological networks are redundant and adaptively resistant. Methods: A comprehensive literature review was conducted to investigate the theoretical basis, design approaches (pharmacophore linking, fusing, and merging), and clinical uses of multi-target agents using network pharmacology and systems biology. Results: Multi-kinase inhibitors (imatinib, sunitinib, cabozantinib) approved by the Food and Drug Administration have shown superior efficacy to traditional monotherapies due to multiple driver inhibition; dual acetylcholinesterase and Beta-site amyloid precursor protein cleaving enzyme 1 inhibitors show enhanced neuroprotective effects against Alzheimer's disease; and β-lactam/βlactamase inhibitor combinations address drug resistance. Artificial intelligence can accelerate target identification, and novel design technologies, such as fragment-based screening, can generate balanced polypharmacology. Discussion: Multi-target strategies are ideal for overcoming redundancy in biological networks and minimizing drug resistance. However, several issues remain, including the complexity of target selection, the need to achieve balanced efficacy across multiple targets, ADMET optimization, and regulatory hurdles. Emerging technologies, such as quantum computing, precision polypharmacology based on multiomics profiling, and digital health integration, could improve target selection and optimization. Conclusion: Multi-target agents are no longer constrained by single-target effects; however, issues of balanced potency, ADMET, and control still exist. The combination of AI, quantum computing, and precision polypharmacology may enable more effective multi-target interventions to address unmet demands in complex diseases.

29 September 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MIMohammed Arfath M I
Mohammed Arfath M I
Akhilesh DubeyAkhilesh Dubey
Akhilesh Dubey
ASAmitha Shetty
Amitha Shetty
HPHaribalan Perumalsamy
Haribalan Perumalsamy
SBSri Renukadevi Balusamy
Sri Renukadevi Balusamy
MMManohar M
Manohar M
Natural bioactive compounds, especially plant-derived phytoconstituents, have gained significant interest due to their structural diversity, multitarget pharmacological activities, and favourable safety profiles. Their pharmaceutical translation is often hindered by poor aqueous solubility, limited membrane permeability, chemical instability, extensive first-pass metabolism, and, therefore, low oral bioavailability. Phytosomes, which are molecular complexes of bioactive compounds with phospholipids, have emerged as a new, effective, lipid-based delivery platform that can overcome these biopharmaceutical limitations and improve solubility, membrane interactions, systemic exposure, and therapeutic efficacy. The present review critically analyses recent advancements in phytosomal drug delivery, from formulation development to clinical translation, focusing on molecular complexation mechanisms, formulation strategies, physicochemical characterisation, pharmacokinetic enhancement, therapeutic applications, and challenges in clinical translation. The current review combines pharmaceutical design principles with recent advances in quality-by-design (QbD), computational formulation optimisation, hybrid phytosomal systems, scalable manufacturing approaches, and targeted delivery strategies. In addition, prospects for the future extension of phospholipid complexation to bioactive compounds from marine organisms, fungi, microorganisms, and algae are discussed in relevance to the next-generation natural product therapeutics. The present review serves as an emerging link between the discovery of natural bioactive compounds and the development of clinically translatable phytosomal systems from a pharmaceutical perspective.